PALATIN TECHNOLOGIES INC
S-3, EX-5, 2000-12-18
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: PALATIN TECHNOLOGIES INC, S-3, 2000-12-18
Next: PALATIN TECHNOLOGIES INC, S-3, EX-23, 2000-12-18





EXHIBIT 5.1, Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

       [letterhead of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.]

December 15, 2000

Palatin Technologies, Inc.
103 Carnegie Center, Suite 200
Princeton, New Jersey 08540

Ladies and gentlemen:

     We have acted as counsel for Palatin Technologies, Inc., a Delaware
corporation (the "Company"), in connection with the preparation of the
Registration Statement on Form S-3 (the "Registration Statement") filed with the
Securities and Exchange Commission (the "Commission") on December 15, 2000 under
the Securities Act of 1933, as amended (the "Act"), for registration under the
Act of the following securities:

     1.   2,532,369 shares of common stock, par value $.01 per share (the
          "Common Stock"), sold in a private placement in September and October
          2000 to certain of the selling stockholders ("Selling Stockholders")
          named in the Registration Statement.

     2.   Up to 506,475 shares of Common Stock issuable upon exercise of the
          Company's Common Stock Warrants ("Private Placement Warrants") issued
          to certain of the Selling Stockholders in conjunction with their
          purchase of Common Stock in the private placement described in
          paragraph 1 above.

     3.   Up to 303,884 shares of Common Stock issuable upon exercise of the
          Company's Common Stock Warrants ("Private Placement Finder's
          Warrants") issued to Privateq Advisors AG as partial compensation for
          its services as a finder in the private placement described in
          paragraph 1 above.

     4.   Up to 50,000 shares of Common Stock issued or issuable upon exercise
          of the Company's Common Stock Warrants ("Watson Termination Warrants")
          issued in April 2000 to certain of the Selling Stockholders in
          connection with the termination of the Company's license agreement
          with Watson Laboratories, Inc.

     As counsel to the Company, we have examined such corporate records,
documents, agreements and such matters of law as we have considered necessary or
appropriate for the purpose of this opinion. Upon the basis of such examination,
we advise you that in our opinion:

     1.   The 2,532,369 shares of Common Stock issued to the Selling
          Stockholders were duly authorized and validly issued by the Company,
          and are fully paid and non-assessable.

<PAGE>

Palatin Technologies, Inc.
December 15, 200
Page 2


     2.   Up to 506,475 shares of Common Stock issuable upon exercise of Private
          Placement Warrants, if and when paid for and issued upon exercise of
          Private Placement Warrants in accordance with the terms thereof, will
          be duly authorized and validly issued by the Company, and will be
          fully paid and non-assessable.

     3.   Up to 303,884 shares of Common Stock issuable upon exercise of Private
          Placement Finder's Warrants, if and when paid for and issued upon
          exercise of Private Placement Finder's Warrants in accordance with the
          terms thereof, will be duly authorized and validly issued by the
          Company, and will be fully paid and non-assessable.

     4.   (a) Up to 41,062 shares of Common Stock issuable upon exercise of
          Watson Termination Warrants, if and when paid for and issued upon
          exercise of Watson Termination Warrants in accordance with the terms
          thereof, will be duly authorized and validly issued by the Company,
          and will be fully paid and non-assessable; and (b) 8,938 shares of
          Common Stock issued upon exercise of Watson Termination Warrants in
          accordance with the terms thereof, are duly authorized and validly
          issued by the Company, and are fully paid and non-assessable.

     We are members of the Bar of the State of New York, and the opinions
expressed herein are limited to questions arising under the laws of the State of
New York, the General Corporation Law of the State of Delaware and the Federal
laws of the United States of America, and we disclaim any opinion whatsoever
with respect to matters governed by the laws of any other jurisdiction.

     We consent to the filing of this opinion as an exhibit to the Registration
Statement and to the references to this firm under the caption "Legal Matters"
in the Prospectus which is a part of the Registration Statement. Reference is
made to the section of the Registration Statement entitled "Legal Matters" for a
description of ownership of the Company's securities by a member of this firm.

                            Very truly yours,

                            MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission